Impact of Lipoprotein(a) Level on Low-Density Lipoprotein Cholesterol– or Apolipoprotein B–Related Risk of Coronary Heart Disease
Authors:
- Fabian J. BrunnerFBFabian J. Brunner
- Tanja ZellerTZTanja Zeller
- Marco M. FerrarioMFMarco M. Ferrario
Abstract
No abstract availableKeywords
Funding Information
- THL
This publication has 27 references indexed in Scilit:
- Trends and consequences of lipoprotein(a) testing: Cross-sectional and longitudinal health insurance claims database analysesAtherosclerosis, 2023
- Quantification of LDL-Cholesterol Corrected for Molar Concentration of Lipoprotein(a)Cardiovascular Drugs and Therapy, 2022
- Lipoprotein(a) measurement issues: Are we making a mountain out of a molehill?Atherosclerosis, 2022
- Measuring the contribution of Lp(a) cholesterol towards LDL-C interpretationClinical Biochemistry, 2020
- Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLMAtherosclerosis, 2020
- Apolipoprotein B Particles and Cardiovascular DiseaseJAMA Cardiology, 2019
- Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular RiskJAMA, 2017
- BiomarCaRE: rationale and design of the European BiomarCaRE project including 300,000 participants from 13 European countriesEuropean Journal of Epidemiology, 2014
- Lipoprotein(a)-cholesterol: A significant component of serum cholesterolClinica Chimica Acta, 2011
- A note on quantifying follow-up in studies of failure timeControlled Clinical Trials, 1996